Want to see CGTX full AI Analyst Report?
Top Page
Cognition Therapeutics
(NASDAQ:CGTX)
Select Model
Select Model
Rating:49Neutral
Price Target:
$1.00
▼(-15.97% Downside)
Action:Reiterated
Date:06/26/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and negative free cash flow) and a soft technical setup with the stock trading below major moving averages. Offsetting these are a low-debt balance sheet and positive corporate developments around progressing zervimesine toward later-stage trials and supportive regulatory dialogue, but these do not fully compensate for current cash-burn and profitability risks.
Positive Factors
Low Leverage / Balance Sheet
Very low debt and a positive equity base reduce refinancing risk and give the company financial flexibility to support clinical programs. For a pre-revenue biotech, minimal leverage lowers bankruptcy probability and preserves optionality to time external financings or partnerships.
Negative Factors
Pre-revenue with Persistent Losses
Sustained operating losses and negative free cash flow mean the company cannot self-fund late-stage trials. Continued high R&D spend without product revenue forces reliance on external capital, which can compress strategic options and increase dilution over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Balance Sheet
Very low debt and a positive equity base reduce refinancing risk and give the company financial flexibility to support clinical programs. For a pre-revenue biotech, minimal leverage lowers bankruptcy probability and preserves optionality to time external financings or partnerships.
Read all positive factors
Cognition Therapeutics (CGTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$100.24M
Dividend YieldN/A
Average Volume (3M)2.91M
Price to Earnings (P/E)―
Beta (1Y)2.72
Revenue GrowthN/A
EPS Growth64.57%
CountryUS
Employees25
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.26
Shares Outstanding89,498,020
10 Day Avg. Volume2,171,776
30 Day Avg. Volume2,911,286
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.87
Price to Sales (P/S)0.00
P/FCF Ratio-4.00
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-572.26
Enterprise Value/Ebitda-3.82
Forecast
1Y Price Target
$3.50Price Target Upside194.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.28
Revenue Forecast (FY)N/A
Cognition Therapeutics Business Overview & Revenue Model
Company Description
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenera...
How the Company Makes Money
As a clinical-stage biotechnology company, Cognition Therapeutics does not primarily generate recurring revenue from marketed products. The company funds operations mainly through external financing (e.g., proceeds from equity offerings such as it...
Cognition Therapeutics Earnings Call Summary
Earnings Call Date:Mar 20, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Neutral
The earnings call highlights significant progress in clinical efficacy signals and strategic cost management, extending the cash runway. However, challenges remain with increased net losses, NASDAQ compliance issues, and uncertain funding partnerships. The sentiment is balanced by advancements in manufacturing and patent filings.Positive Updates
Strong Efficacy Signals for Zervimesine
The company reported strong efficacy signals from two studies involving Alzheimer's disease and dementia with Lewy bodies (DLB), indicating potential value for patients and investors.
Negative Updates
Net Loss Increase
The company reported a net loss of $34 million for the year ended December 31, 2024, compared to a net loss of $25.8 million in 2023, despite a decrease in general and administrative expenses.
Read all updates
Q4-2024 Updates
Positive
Negative
Strong Efficacy Signals for Zervimesine
The company reported strong efficacy signals from two studies involving Alzheimer's disease and dementia with Lewy bodies (DLB), indicating potential value for patients and investors.
Read all positive updates
Company Guidance
During the Cognition Therapeutics Fourth Quarter and Full Year 2024 Earnings Call, the company provided guidance on advancing their lead candidate, zervimesine (CT1812), into registrational trials for Alzheimer's disease and dementia with Lewy bodies (DLB). The company plans to submit final study documents to the FDA and request end of Phase II meetings for both indications. Their strategic decision to conclude the Phase II dry AMD study was made to focus resources on Alzheimer's and DLB programs, extending their cash runway into Q4 2025. Cognition reported a net loss of $34 million for 2024 and utilized an ATM facility to raise $12.8 million. They hold approximately $25 million in cash and $50 million in obligated grant funds. The company is also working on securing non-dilutive funding and is confident in regaining NASDAQ compliance within the allotted grace period.Cognition Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
25
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -129.00K | 0.00 | 0.00 | 0.00 | -235.00K | 0.00 |
| EBITDA | -19.31M | -23.25M | -33.68M | -25.51M | -21.13M | -10.73M |
| Net Income | -19.58M | -23.49M | -33.97M | -25.79M | 757.00K | -11.72M |
Balance Sheet | ||||||
| Total Assets | 36.14M | 48.39M | 30.23M | 35.16M | 50.42M | 59.14M |
| Cash, Cash Equivalents and Short-Term Investments | 31.13M | 36.81M | 25.01M | 29.92M | 41.56M | 54.72M |
| Total Debt | 465.00K | 638.00K | 814.00K | 1.24M | 1.48M | 0.00 |
| Total Liabilities | 6.23M | 14.12M | 11.48M | 10.69M | 10.18M | 7.86M |
| Stockholders Equity | 29.91M | 34.27M | 18.75M | 24.47M | 40.25M | 51.27M |
Cash Flow | ||||||
| Free Cash Flow | -20.25M | -24.59M | -28.48M | -16.16M | -18.70M | -3.66M |
| Operating Cash Flow | -20.25M | -24.59M | -28.47M | -16.02M | -18.53M | -3.63M |
| Investing Cash Flow | 9.00K | 9.00K | -4.00K | -147.00K | -171.00K | -27.00K |
| Financing Cash Flow | 35.04M | 36.57M | 23.57M | 4.52M | 5.55M | 53.20M |
Cognition Therapeutics Technical Analysis
Negative
1.19
Price Trends
1.24
Negative
1.13
Negative
1.35
Negative
Market Momentum
0.01
Positive
44.27
Neutral
17.81
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGTX, the sentiment is Negative. The current price of 1.19 is below the 20-day moving average (MA) of 1.29, below the 50-day MA of 1.24, and below the 200-day MA of 1.35, indicating a bearish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 44.27 is Neutral, neither overbought nor oversold. The STOCH value of 17.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CGTX.
Cognition Therapeutics Risk Analysis
Cognition Therapeutics disclosed 86 risk factors in its most recent earnings report. Cognition Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cognition Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $948.94M | -10.90 | -47.22% | ― | ― | -6.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $100.24M | -4.27 | -72.68% | ― | ― | 64.57% | |
49 Neutral | $210.74M | -0.90 | -67.65% | ― | 74.84% | 99.51% | |
47 Neutral | $78.24M | -0.56 | -80.35% | ― | ― | 27.27% | |
47 Neutral | $154.38M | -1.82 | -339.38% | ― | ― | 17.64% | |
44 Neutral | $76.34M | -1.69 | -2748.16% | ― | ― | 43.68% |
* Healthcare Sector Average
CGTX
Cognition Therapeutics
1.12
0.81
261.29%
TNXP
Tonix Pharma
13.22
-22.76
-63.26%
ACET
Adicet Bio
8.37
-1.39
-14.24%
MIST
Milestone Pharmaceuticals
1.24
-0.70
-36.08%
ELTX
Elicio Therapeutics
4.00
-3.72
-48.19%
ANRO
Alto Neuroscience, Inc.
27.04
24.84
1129.09%
Cognition Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Cognition Therapeutics Shareholders Elect Directors, Ratify Auditor
Positive
Jun 18, 2026
On June 17, 2026, Cognition Therapeutics, Inc. held its Annual Meeting of Stockholders virtually, at which shareholders elected Aaron Fletcher, Ph.D., and Lisa Ricciardi as Class II directors to serve until the 2029 Annual Meeting, underscoring co...
Business Operations and StrategyProduct-Related Announcements
Cognition Therapeutics Advances Zervimesine Toward Phase 3 DLB Trial
Positive
Jun 4, 2026
Cognition Therapeutics has furnished an investor presentation outlining the advancement of its lead oral candidate zervimesine toward a planned Phase 3 registrational program in dementia with Lewy bodies psychosis, citing SHIMMER Phase 2 data show...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Cognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial
Positive
May 21, 2026
On May 20, 2026, Cognition Therapeutics held a planned meeting with the U.S. Food and Drug Administration to review Phase 2 results for its lead candidate zervimesine (CT1812) in dementia with Lewy bodies patients with psychosis. The discussion fo...
Business Operations and StrategyFinancial Disclosures
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress
Positive
Mar 26, 2026
On March 26, 2026, Cognition Therapeutics reported fourth-quarter and full-year 2025 results and detailed progress in advancing its lead drug zervimesine for neurodegenerative indications. The company is prioritizing development of zervimesine for...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.